Logo

Arbor Biosciences MyNGS Guides MitoDeplete Kits

Jun 06, 2019

Arbor Biosciences, a division of Chiral Technologies, has launched MyNGS Guides MitoDeplete Kits as part of its catalog of guide RNA pools for targeted sequencing applications. This new depletion system combines Arbor's massively parallel, high-fidelity oligo synthesis platform with Cas enzymes for efficiently targeting unwanted molecules from NGS libraries. In-stock MitoDeplete catalog kits have been designed and validated for human and mouse applications, and the company can design and synthesize kits for other custom species on demand.

MitoDeplete kits are designed for use on any NGS library containing a significant percentage of mitochondrial DNA molecules, such as ATAC-Seq libraries. CRISPR-based depletion with MitoDeplete delivers up to a 95 percent reduction in mtDNA-derived molecules in a single-step process. The human and mouse kits are available for immediate shipment in an eight-reaction kit size. Kits for custom species can be produced on request through collaboration with one of the product scientists at Arbor.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.